AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Vaxcyte, Inc.
Video analysis: PCVX
All videosNo video analysis for this stock yet. Request one from our team.
News: PCVX
Vaxcyte Target of Unusually High Options Trading (NASDAQ:PCVX)
Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) was the recipient of some unusual options trading on Tuesday. Stock investors acquired 3,549 put options on the company. This is an increase of approximately 52% compared to the typical daily volume of 2,333 put options. Analyst Ratings Changes Several equities analysts have recently issued reports on the
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing
Andrew Guggenhime surrendered 2,705 shares at $61.18 per share on August 31 and September 2, representing a transaction value of $165,492. The transaction size represents 2% of the total equity stake held before the filing.
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know
The transactions represented a combined value of about $378,000 based on weighted average prices of $61.12 per share. Jim Wassil traded shares equal to 4% of the stake held before the filing.
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm
The disposition of 6,289 shares at $61.20 per share represented a transaction value of about $384,900. The transaction involved shares equal to 0.87% of the total equity stake held before the filing, resulting in a minor reduction of the overall position.
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
Luis Jodar, Ph.D., Former Pfizer Chief Medical Officer for Vaccines and Infectious Diseases with Extensive Leadership Experience Across Clinical Development and Medical Affairs for Pneumococcal Conjugate Vaccines Prevnar 13 and Prevnar 20, Joins Vaxcyte as Chief Medical Officer
Vaxcyte to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in fireside chats and host one-on-one meetings at the following investor conferences:
Deutsche Bank AG Makes New $15.02 Million Investment in Vaxcyte, Inc. $PCVX
Deutsche Bank AG bought a new position in Vaxcyte, Inc. (NASDAQ: PCVX) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 258,338 shares of the company's stock, valued at approximately $15,017,000. Deutsche Bank AG owned 0.18% of Vaxcyte
If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone
Seth Klarman's Baupost Group eliminated its entire stake in Vaxcyte (NASDAQ:PCVX | PCVX Price Prediction) during the June quarter, according to the 13F filed August 13, 2026.
